enGene Therapeutics Inc. filed a Form 8-K on November 12, 2026, reporting pivotal Phase 2 LEGEND trial results for detalimogene, FDA alignment on a planned Biologics License Application, and preliminary fiscal year-end cash of approximately $245.8 million.

Key Highlights

  • LEGEND Trial Results: The company announced results from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial of detalimogene on November 11, 2026.
  • FDA Alignment: According to the filing, the company disclosed alignment with the FDA on key components of the planned Biologics License Application for detalimogene.
  • Preliminary Cash Position: The company expects to report approximately $245.8 million in cash, cash equivalents, and marketable securities as of October 31, 2026.
  • Fiscal Year End: The preliminary financial figures relate to the fiscal year ended October 31, 2026, though financial statements have not yet been finalized.
  • Updated Presentations: The company updated its Corporate Presentation and Investor Presentation, furnished as Exhibits 99.1 and 99.2.
  • Unaudited Estimates: The filing notes that KPMG LLP "has not audited, reviewed, examined, compiled, or applied agreed-upon procedures with respect to the preliminary financial information."

enGene Discloses LEGEND Cohort 1 Data and BLA Pathway for Detalimogene

On November 11, 2026, enGene Therapeutics Inc. (NASDAQ:ENGN), a biopharmaceutical company incorporated in British Columbia and headquartered in Saint-Laurent, Quebec, Canada, announced results from the pivotal Cohort 1 of its Phase 2 LEGEND trial evaluating detalimogene. According to the filing, the company also disclosed that it has reached alignment with the FDA on key components of the planned Biologics License Application. A press release issued in connection with the announcement was attached as Exhibit 99.3.

In the same filing, the company provided preliminary financial information for its fiscal year ended October 31, 2026. The company disclosed it expects to report approximately $245.8 million in cash, cash equivalents, and marketable securities as of that date. The filing cautions that these figures have not been finalized and "are subject to its financial closing procedures and any final adjustments that may be made prior to the time its financial results for Fiscal Year 2026 are finalized and filed with the SEC." Management further stated the company "assumes no duty to update these preliminary estimates except as required by law."

The filing also notes that the company updated both its Corporate Presentation and its Investor Presentation on November 11, 2026, furnished as exhibits under Item 7.01 Regulation FD Disclosure. The disclosures under Item 7.01 are expressly stated in the filing as not being "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. The company identifies itself as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.

What Was Disclosed

enGene Therapeutics filed an 8-K reporting pivotal Phase 2 LEGEND trial results for detalimogene, FDA alignment on a BLA, and preliminary fiscal year 2026 cash of approximately $245.8 million, with final figures subject to closing procedures.